FDA Drug Advertising Study Tracker

Posted 12 January 2015 By Alexander Gaffney, RAC

The US Food and Drug Administration (FDA) frequently studies consumer behavior, particularly as it relates to how members of the public (and medical professionals) understand pharmaceutical advertising. Our FDA Drug Advertising Study Tracker keeps tabs on these studies and explains what they're trying to accomplish in plain terms.

DateTopicStudy Summary
January 2012Corrective AdvertisingStudy to assess whether and how corrective advertising—used to correct information in a previous ad—works.
October 2012Promotional Ads and Healthcare ProfessionalsStudy to assess how advertisements and promotional materials affect prescribing habits.
May 2013Composite ScoresStudy to assess whether and how consumers understand "composite scores" used in DTC advertising.
July 2013Health Information AvailabilityAssessment of how consumers find health information about prescription medication
October 2013Adolescents and DTC AdvertisingStudy to assess how adolescents interpret drug risk in DTC advertising
February 2014Alternate Format for Major Risks in DTC Drug AdsProposed study of whether FDA should allow DTC ads to contain only the major risks associated with a drug.
May 2014Distractions in DTC AdvertisingStudy to assess whether "distractions" in DTC advertisements can make a drug seem safer than it is.
November 2014Effects of Repeated Exposure to DTC AdvertisingStudy to assess how repeated exposure to a single drug ad changes consumer behavior over time.
November 2014Impact of Spouse on Understanding of Drug Risks, BenefitsStudy to assess the "social contexts" a drug advertisement is seen in, with a focus on how a spouse can affect risk perception.
November 2014Risk and Benefit Perception Scale DevelopmentStudy to develop reliable measurements of how consumers assess the benefits and risks of drug products.
January 2014Disclosure Regarding Additional Risks in DTC Prescription Drug TV AdvertisementsStudy of how changes to DTC advertising—specifically limiting warnings to the major risks of a drug—might improve the advertisements.

Share this article:

Categories: Biologics and biotechnology, Drugs, Labeling, News, US, CDER, Advertising and Promotion

Tags: Direct-to-Consumer Drug Advertising, DTC Drug Advertising, FDA Regulation of Drug Advertising, FDA Studies

Regulatory Exchange: Latest Updates From the Community